Show simple item record

dc.contributor.authorMontiel-Troya, María
dc.contributor.authorMohamed-Mohamed, Himan
dc.contributor.authorPardo-Moreno, Teresa
dc.contributor.authorGonzález-Díaz, Ana
dc.contributor.authorRúger Navarrete, Azahara
dc.contributor.authorde la Mata Fernández, Mario
dc.contributor.authorTovar Gálvez, María Isabel
dc.contributor.authorRamos-Rodríguez, Juan José
dc.contributor.authorGarcía Morales, Victoria 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2025-03-13T08:37:43Z
dc.date.available2025-03-13T08:37:43Z
dc.date.issued2024
dc.identifier.issn2227-9059
dc.identifier.urihttp://hdl.handle.net/10498/35837
dc.description.abstract(1) Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease in which the patient suffers from an affection of both upper and lower motor neurons at the spinal and brainstem level, causing a progressive paralysis that leads to the patient’s demise. Gender is also considered a predisposing risk factor for developing the disease. A brief review of the pathophysiological mechanisms of the disease is also described in this work. Despite the fact that a cure for ALS is currently unknown, there exists a variety of pharmacological and non-pharmacological therapies that can help reduce the progression of the disease over a certain period of time and alleviate symptoms. (2) We aim to analyze these pharmacological and non-pharmacological therapies through a systematic review. A comprehensive, multidisciplinary approach to treatment is necessary. (3) Drugs such as riluzole, edaravone, and sodium phenylbutyrate, among others, have been investigated. Additionally, it is important to stay updated on research on new drugs, such as masitinib, from which very good results have been obtained. (4) Therapies aimed at psychological support, speech and language, and physical therapy for the patient are also available, which increase the quality of life of the patients.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBiomedicines - 2024, Vol. 12 n. 10, artículo n. 2200es_ES
dc.subjectALSes_ES
dc.subjectamyotrophic lateral sclerosises_ES
dc.subjectmotor neuron dysfunctiones_ES
dc.subjectmultidisciplinary treatmentes_ES
dc.subjectneurodegenerative disorderes_ES
dc.subjectpharmacological interventionses_ES
dc.titleAdvancements in Pharmacological Interventions and Novel Therapeutic Approaches for Amyotrophic Lateral Sclerosises_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/biomedicines12102200
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-110960GB-I00/ES/P11, UN NUEVO MEDIADOR EN NEUROTRANSMISION Y PLASTICIDAD SINAPTICA EN EL SNC/ es_ES
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional